Compare PubMatic Inc (PUBM) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PubMatic Inc vs 10X Genomics Inc — how do they compare? PubMatic Inc trades at $18.64 (market cap $850.88M), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 11.8× PubMatic Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold PubMatic Inc for 40 Days and 10X Genomics Inc for 91 Days on average.
| PUBM | TXG | |
|---|---|---|
Market Cap | $850.88M | $10.07B |
Volume | 997,698 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $19.18 | $97.74 |
52-Week Low | $6.28 | $11.48 |
Typical Hold Time | 40 Days | 91 Days |
Enterprise Value | $754.01M | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PUBM trades at $18.68, up 0.59% today, with a bullish technical signal supported by moving averages. The company reported a net loss of $14.46 million in 2025 despite revenue of $282.93 million, though recent quarters have shown earnings beats. Analyst sentiment is positive with a $19.89 consensus price target and 11 buy ratings. Recent news highlights AI-driven ad tech growth and leadership changes, including a new global chief revenue officer.
The outlook is cautiously optimistic given strong analyst support and technical momentum, but profitability challenges and competitive pressures in digital advertising pose risks. Revenue growth and margin improvement in higher-margin segments like mobile and CTV are key catalysts for upside, while execution risks and market volatility remain concerns.
10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.
The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
